Key Highlights

• ABBV shares rose 3.16% intraday to $259.01, moving toward a new 52-week high.

• The company secured dual positive CHMP opinions for RINVOQ in severe alopecia areata and non-segmental vitiligo.

• A Phase 3 trial showed epcoritamab reduced progression risk by approximately 60% in relapsed or refractory DLBCL.

• AbbVie completed its acquisition of Apogee Therapeutics on June 22.

Regulatory and Clinical Wins Drive Shares Higher

AbbVie Inc. (NYSE:ABBV) shares advanced Thursday, outperforming the broader healthcare sector as investors reacted to a wave of positive clinical and regulatory catalysts. The company secured dual positive opinions from the European Committee for Medicinal Products for Human Use recommending RINVOQ for both severe alopecia areata and non-segmental vitiligo, positioning it as potentially the first oral treatment approved in Europe for both conditions.

AbbVie is a North Chicago, Illinois-based global biopharmaceutical company focused on immunology, oncology, aesthetics, neuroscience, eye care, virology and women's health, with a portfolio anchored by blockbuster immunology products including HUMIRA, SKYRIZI and RINVOQ.

Oncology Data and M&A Add to Catalysts

The company also reported a Phase 3 win for epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, showing approximately a 60% reduction in progression risk. This follows AbbVie's June 22 acquisition of Apogee Therapeutics, which had sparked a single-day move of more than 6% at the time, underscoring investor interest in the company's expanding late-stage immunology pipeline.

AbbVie currently trades at a market capitalization exceeding $457 billion, with a price-to-earnings ratio near 25.4 and a dividend yield of 2.60%.

Conclusion

The combination of European regulatory momentum for RINVOQ and strong oncology trial data reinforces AbbVie's positioning across its core immunology and hematology franchises. With the Apogee acquisition also adding to the company's late-stage pipeline, continued regulatory and clinical progress will remain central to the stock's trajectory.

 

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.